Ford Sinks Slightly on Recalls
Ford Motor (NYSE:F) is recalling nearly 1.1 million vehicles in the United States because rearview cameras may not display images due to a software issue, increasing the risk of a crash.The recall covers some 2021 through 2024 model year Bronco, F-150, Edge, and 2023-2024 Escape, Corsair, F-250, F-350, F-450, F-550 and F-600 vehicles, the automaker said Wednesday in a filing with the National Highway Traffic Safety Administration.The recall also impacts the 2022-2024 Expedition, 2022-2025 Transit, 2021-2023 Mach-E, Lincoln Nautilus, 2024 Ranger, Mustang and the 2022-2024 Navigator.NHTSA said the software issue may cause the rearview camera image to delay, freeze, or not display.Ford said it is aware of one allegation of a minor crash resulting in property damage tied to the issue.In January, NHTSA contacted Ford regarding allegations of more than three dozen rear-view camera complaints on 2021-2023 Ford F-150 vehicles.In April, a Ford engineering team was able to reproduce the failure mode within a vehicle and link the causal factors to specific software variants.Dealers are expected to update vehicle software through an over-the-air update. The software being recalled serves as an operating system for the car’s dashboard, helping its infotainment system to control apps and display maps, among others.F shares subtracted three cents to $10.28.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


